🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proximity of large bowel would have made this renal SABR tricky. Hyaluronic Acid HA to the rescue with retroperitoneal spacing to facilitate stressless SABR. Life is indeed easier with HA. #radonc Barrigel

Mike Chao Barrigel We have been using dermal filler. An expert IR does that. And SBRT and other radical treatments are way easier. It doesn’t migrate.Even after years of F/U.We mix it with contrast so better visibility.The contrast disappears rapidly so we try to do the contouring right after.

#KEYNOTE689 is fantastic work. Kudos to the investigators! In addition to Dr. Akhade's commentary, here are a few key points on nested vs. adjacent subgroup reporting in this NEJM study: ✅ Nested reporting of CPS ≥1 subgroup ✅ Benefit within CPS 1–10 = NR ✅ Adjacent

Jeff Ryckman NEJM Prior KEYNOTE studies reported CPS > 20, but twice the number of CPS > 10 to 1-10 is notably different than prior studies and certainly could impact the CPS >1 results.

Key nuance from this paper: Radiotherapy significantly REDUCED the seeding of **NEW** metastases, but it triggers a local wound-healing response that can promote growth of **EXISTING** metastases. The authors elegantly showed that this resistance mechanism to RT is targetable

Jeff Ryckman Dr. Foxpaws Fauxpas Dr Akhil Santhosh ESMO - Eur. Oncology Dr. Nina Niu Sanford There are some data suggesting that higher radiation doses may help achieve greater pCR rates, though the evidence remains limited (link.springer.com/article/10.124…). Not sure there are a lot of great data to push for the higher radiation dose that we use in North America. With TOPGEAR,

🚨ACCORD Trial🚨 Resected Extrahepatic CCA or Gallbladder CA 🔍Randomized Adjuvant CRT + Camrelizumab vs Observation 🔥Whopping improvement in OS and RFS with CRT + ICI with persistent separate at tail of the curve!!! tinyurl.com/64yc3uum JAMA Oncology

Krishan Jethwa JAMA Oncology So. Uh. Maybe it was the CRT?

Jeff Ryckman Susannah Ellsworth JAMA Oncology radoncreview_org While I agree that the observation arm is worthy of critique, I can understand how the investigators chose it- BILCAP did not meet its primary endpoint per ITT analysis. So... we must interpret in context! It's nice to see another option with a very notable ⬆️in OS

Great work out in European Urology Oncology led by Jesus E. Juarez C. outstanding PGY-5 UCLA Jonsson Comprehensive Cancer Center . Pooled analysis of two trials of androgen annihilation (ADT+AAP+apa) and RP/RT plus MDT in de novo mHSPC or oligorecurrent mHSPC euoncology.europeanurology.com/article/S2588-…

European Urology Oncology Jesus E. Juarez C. UCLA Jonsson Comprehensive Cancer Center Notably, the metachronous subgroup with prior ADT had worse outcomes, suggesting increasing resistance with repeated systemic therapy.

I can state without reservation that Amir Safavi is one of the most promising shooting stars in our field. Even before he was blessed to be fellowship trained by the great Nancy Lee. #radonc Nancy Lee

Listening to audience questions at this year’s ASCO meeting has made me hopeful. Change is happening. The questions being asked at annual meetings are changing from cheerleading-type questions to critical inquiry type questions. medscape.com/viewarticle/do…

For historical records, Dept of Radiology (diagnostic and therapeutic) was started in 1919 by Gordon Richards Radiation Oncology. Cobalt was the source at that time He established a novel treatment for cancer and inspired many future leaders including Vera Peters radonc.utoronto.ca/our-history

Erman Akkus Journal of the @NCCN OncoAlert M. Bolton Jeff Ryckman Nice paper. 70% of pts were treated in 1-3 fractions, which is no longer used due to high toxicity. The MRI SMART trial & MSKCC series showed lower toxicity (including later – SMART median f/u 23 months though from diagnosis) with 5, 15 & 25 fractions with modern tech, so

Jeff Ryckman Heres a barrigel one from Dr Chao pubmed.ncbi.nlm.nih.gov/40162340/ Utilization of a stabilized hyaluronic acid spacer in SBRT for retroperitoneal cancers: A case series and dosimetric analysis - PubMed

Jeff Ryckman Shankar Siva x.com/drmikechao/sta…

Mohammed Almahmoud Jeff Ryckman Shankar Siva Thanks Mohammed Almahmoud It’s now published. See CTRO Utilization of sHA spacer in SBRT for retroperitoneal cancers: A case series and dosimetric analysis. Doi:10.1016/j.ctro.2025.100943